IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.
Metrics to compare | 461030 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship461030PeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.3x | −13.7x | −0.4x | |
PEG Ratio | −0.54 | −0.27 | 0.00 | |
Price/Book | 3.6x | 2.2x | 2.6x | |
Price / LTM Sales | 16.8x | 15.5x | 3.2x | |
Upside (Analyst Target) | - | 65.3% | 50.6% | |
Fair Value Upside | Unlock | 5.9% | 6.6% | Unlock |